264 related articles for article (PubMed ID: 32729743)
21. Statin Intolerance: A Review and Update.
Tsushima Y; Hatipoglu B
Endocr Pract; 2023 Jul; 29(7):566-571. PubMed ID: 36958647
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and Management of Statin Intolerance.
Alonso R; Cuevas A; Cafferata A
J Atheroscler Thromb; 2019 Mar; 26(3):207-215. PubMed ID: 30662020
[TBL] [Abstract][Full Text] [Related]
23. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
24. Overcoming patient reluctance to statin intolerance.
Katamesh BE; Mickow AA; Huang L; Dougan BM; Ratrout BM; Nanda S; Vincent A
Kardiol Pol; 2024; 82(5):485-491. PubMed ID: 38712783
[TBL] [Abstract][Full Text] [Related]
25. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.
Chien SC; Chen PS; Huang YH; Tang SC; Li YH; Yeh HI
J Formos Med Assoc; 2019 Oct; 118(10):1385-1392. PubMed ID: 30584005
[TBL] [Abstract][Full Text] [Related]
26. Statin use and safety concerns: an overview of the past, present, and the future.
Mulchandani R; Lyngdoh T; Kakkar AK
Expert Opin Drug Saf; 2020 Aug; 19(8):1011-1024. PubMed ID: 32668998
[TBL] [Abstract][Full Text] [Related]
27. Identification of Patients with Statin Intolerance in a Managed Care Plan: A Comparison of 2 Claims-Based Algorithms.
Bellows BK; Sainski-Nguyen AM; Olsen CJ; Boklage SH; Charland S; Mitchell MP; Brixner DI
J Manag Care Spec Pharm; 2017 Sep; 23(9):926-934. PubMed ID: 28854079
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
[TBL] [Abstract][Full Text] [Related]
29. Statin intolerance.
Ahmad Z
Am J Cardiol; 2014 May; 113(10):1765-71. PubMed ID: 24792743
[TBL] [Abstract][Full Text] [Related]
30. Statin myopathy: over-rated and under-treated?
Maghsoodi N; Wierzbicki AS
Curr Opin Cardiol; 2016 Jul; 31(4):417-25. PubMed ID: 27258372
[TBL] [Abstract][Full Text] [Related]
31. MY APPROACH to Managing Statin-Associated Muscle Symptoms.
Thompson PD
Trends Cardiovasc Med; 2017 Feb; 27(2):160-161. PubMed ID: 28107840
[No Abstract] [Full Text] [Related]
32. [Statin intolerance and associated muscular dysfunctions].
Boulanger-Piette A; Bergeron J; Desgreniers J; Côté-Levesque M; Brassard D; Joanisse DR; Frenette J
Med Sci (Paris); 2015 Dec; 31(12):1109-14. PubMed ID: 26672664
[TBL] [Abstract][Full Text] [Related]
33. Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
Kondo Y; Hamai J; Nezu U; Shigematsu E; Kamiko K; Yamazaki S; Yoshii T; Takahashi M; Takano T; Kawasaki S; Yamada M; Yamakawa T; Terauchi Y
Endocr J; 2014; 61(4):343-51. PubMed ID: 24452015
[TBL] [Abstract][Full Text] [Related]
34. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.
Sharma M; Ansari MT; Abou-Setta AM; Soares-Weiser K; Ooi TC; Sears M; Yazdi F; Tsertsvadze A; Moher D
Ann Intern Med; 2009 Nov; 151(9):622-30. PubMed ID: 19884623
[TBL] [Abstract][Full Text] [Related]
35. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
Soska V
Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
[TBL] [Abstract][Full Text] [Related]
36. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A; Thompson D; Whitehouse A; Collier T; Dahlof B; Poulter N; Collins R; Sever P;
Lancet; 2017 Jun; 389(10088):2473-2481. PubMed ID: 28476288
[TBL] [Abstract][Full Text] [Related]
37. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
38. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
39. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
[TBL] [Abstract][Full Text] [Related]
40. Statin intolerance: why and what to do - with a focus on diabetic people.
Matteucci E; Giampietro O
Curr Med Chem; 2013; 20(11):1397-408. PubMed ID: 23394553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
